I agree that this site is using cookies. You can find further informations here.
X
Cerchione, C.
79  results:
Search for persons X
?
1

P557: HEMATOLOGIC IMPROVEMENTS WITH IVOSIDENIB + AZACITIDIN..:

Dohner, H. ; Montesinos, P. ; Vives Polo, S....
HemaSphere.  6 (2022)  - p. 456-457 , 2022
Link: https://doi.org/10.1097/..
 
?
2

PB1985: CHEMO OR CHEMO-FREE REGIMENS IN HEAVILY PRETREATED ..:

Cerchione, C. ; Nappi, D. ; Pareto, A. E....
HemaSphere.  6 (2022)  - p. 1857-1858 , 2022
Link: https://doi.org/10.1097/..
 
?
3

PB1987: DOMESTIC OPPORTUNITY IN HEAVILY PRETREATED MULTIPLE..:

Cerchione, C. ; Nappi, D. ; Pareto, A. E....
HemaSphere.  6 (2022)  - p. 1859-1860 , 2022
Link: https://doi.org/10.1097/..
 
?
4

PB1984: ELOTUZUMAB PLUS LENALIDOMIDE AND DEXAMETHASONE IN R..:

Bruzzese, A. ; Derudas, D. ; Galli, M....
HemaSphere.  6 (2022)  - p. 1856-1857 , 2022
Link: https://doi.org/10.1097/..
 
?
5

P1288: ALTERED AMINO ACID HOMEOSTASIS CAN ELICIT AN ADAPTIV..:

Romano, A. ; Scandura, G. ; Tibullo, D....
HemaSphere.  6 (2022)  - p. 1173-1174 , 2022
Link: https://doi.org/10.1097/..
 
?
6

PB2263: SUPPORTIVE CARE IN LOW-RISK MYELODYSPLASTIC SYNDROM..:

Cerchione, C. ; Musuraca, G. ; Giannini, B....
HemaSphere.  6 (2022)  - p. 2133-2134 , 2022
Link: https://doi.org/10.1097/..
 
?
7

PB1986: ADDITION OF CARFILZOMIB AS A THIRD AGENT IN LENALID..:

Cerchione, C. ; Nappi, D. ; Pareto, A. E....
HemaSphere.  6 (2022)  - p. 1858-1859 , 2022
Link: https://doi.org/10.1097/..
 
?
8

PB2262: PEGFILGRASTIM IN THE SUPPORTIVE CARE OF HEAVILY PRE..:

Cerchione, C. ; Nappi, D. ; Pareto, A. E....
HemaSphere.  6 (2022)  - p. 2132-2133 , 2022
Link: https://doi.org/10.1097/..
 
?
9

PET/MRI for staging patients with Hodgkin lymphoma: equival..:

Picardi, M. ; Cavaliere, C. ; Della Pepa, R....
Annals of Hematology.  100 (2021)  6 - p. 1525-1535 , 2021
Link: https://doi.org/10.1007/..
 
?
10

PCN224 An Italian Experience: How the COVID-19 Era HAS Modi..:

Rossi, A. ; Prochowski Iamurri, A. ; Cerchione, C....
Value in Health.  23 (2020)  - p. S462-S463 , 2020
Link: https://doi.org/10.1016/..
 
?
11

Pomalidomide-dexamethasone in the management of heavily pre..:

Cerchione, C. ; Catalano, L. ; Nappi, D....
Hematology, Transfusion and Cell Therapy.  42 (2020)  - p. 55 , 2020
Link: https://doi.org/10.1016/..
 
?
12

Bendamustine-bortezomib-dexamethasone (BVD) in heavily pret..:

Cerchione, C. ; Catalano, L. ; Nappi, D....
Hematology, Transfusion and Cell Therapy.  42 (2020)  - p. 22 , 2020
Link: https://doi.org/10.1016/..
 
?
13

Carfilzomib-lenalidomide-dexamethasone in the management of..:

Cerchione, C. ; Catalano, L. ; Nappi, D....
Hematology, Transfusion and Cell Therapy.  42 (2020)  - p. 55-56 , 2020
Link: https://doi.org/10.1016/..
 
?
14

PCN216 An Innovative Organization MODEL to Face Risks Reduc..:

Gentili, N. ; Roncadori, A. ; Massa, I....
Value in Health.  23 (2020)  - p. S461 , 2020
Link: https://doi.org/10.1016/..
 
?
15

KRD (carfilzomib and lenalidomide plus dexamethasone) for t..:

Palmieri, Salvatore ; Rocco, S. ; Vitagliano, O....
Annals of Hematology.  99 (2020)  12 - p. 2903-2909 , 2020
Link: https://doi.org/10.1007/..
 
1-15